Non-randomized, open label phase II trial evaluating the safety and efficacy of taxotere (T) followed by myocet (M) + cyclophosphamide (C) as first-line treatment for HER2-negative breast cancer (BC)
Services
Services
Date issued
2011Journal title
CANCER RESEARCH
Type of content
Publicación de congreso
